<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We used <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (PET) to study brain [<z:chebi fb="4" ids="36929">11C</z:chebi>]<z:chebi fb="0" ids="5103">flumazenil</z:chebi> (FMZ) binding in four <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome (AS)</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Patients 1 to 3 had a maternal deletion of 15q11-q13 leading to the loss of beta3 subunit of gamma-aminobutyric acidA/<z:chebi fb="13" ids="22720">benzodiazepine</z:chebi> (<z:chebi fb="3" ids="16865">GABA</z:chebi>(A)/BZ) receptor, whereas Patient 4 had a mutation in the ubiquitin protein ligase (UBE3A) saving the beta3 subunit gene </plain></SENT>
<SENT sid="2" pm="."><plain>[<z:chebi fb="4" ids="36929">11C</z:chebi>]FMZ binding potential in the frontal, parietal, hippocampal, and cerebellar regions was significantly lower in Patients 1 to 3 than in Patient 4 </plain></SENT>
<SENT sid="3" pm="."><plain>We propose that the 15q11-q13 deletion leads to a reduced number of <z:chebi fb="3" ids="16865">GABA</z:chebi>(A)/BZ receptors, which could partly explain the neurological deficits of the AS patients </plain></SENT>
</text></document>